03:53 AM EDT, 06/28/2024 (MT Newswires) -- Merck ( MRK ) said late Thursday that the US Centers for Disease Control and Prevention's Advisory Committee unanimously voted to recommend its pneumococcal vaccination, Capvaxivetm, as an option for adults 65 and older.

The committee has recommended a single dose of the vaccine in adults over 65 and adults 19 to 64 with certain risk conditions who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown.

Additionally, the company said the committee has recommended using its vaccine as a supplemental dose in adults over 65 who have completed their vaccine series with both PCV13 and PPSV23.

These recommendations will become official after review and approval by the CDC director and the Department of Health and Human Services.

Price: 130.00, Change: +0.18, Percent Change: +0.14